The most active compounds were further tested in wound-healing assays, where 3lPd almost completely inhibited A549 cell migration at 24 and 48 h, whereas the reference drug cisplatin induced only partial inhibition...In silico studies were performed to investigate their interactions with p53, GAPDH, and c-MYC proteins. Overall, these results suggest that piperidine-bearing hydrazones and their Pt(II)/Pd(II) complexes represent promising scaffolds for the development of novel anticancer agents.

P=N/A, N=150, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

P1, N=19, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P3, N=398, Not yet recruiting, NRG Oncology

P=N/A, N=43, Enrolling by invitation, Eye & ENT Hospital of Fudan University

This study delineates a complex spatial architecture of brain tissue with post-treatment changes and its discrepancies from progressive GB, thus facilitating future research into novel treatment strategies.

We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.

GRK2 plays a crucial role in cisplatin-induced nephrotoxicity by modulating NOX4, suggesting that targeting GRK2 is an effective renoprotective strategy for cisplatin-based cancer therapy.

P3, N=88, Completed, Cairo University

P=N/A, N=55, Recruiting, University College Cork | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Oct 2026 --> Jul 2027

This study reports AGP regimen as a promising therapeutic modality for PDAC, and provides a detailed mechanism by which a STING-mediated signaling relay from PDAC tumor cells to TAMs boost antitumor immunity and contribute to AGP chemotherapy efficacy. Furthermore, STING expression in tumor tissues correlated with improved prognosis, highlighting its potential as a predictive biomarker and promising therapeutic target.

In conclusion, propofol enhances cisplatin chemosensitivity in NSCLC by activating Parthanatos through modulation of METTL3-mediated PARP-1 m6A modification. These findings provide mechanistic insight into propofol-mediated reversal of chemoresistance and identify the METTL3-PARP-1-Parthanatos axis as a potential therapeutic target in NSCLC.